vs
Aurinia Pharmaceuticals Inc.（AUPH）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Aurinia Pharmaceuticals Inc.的季度营收约是RE/MAX Holdings, Inc.的1.1倍（$77.1M vs $71.1M），Aurinia Pharmaceuticals Inc.净利率更高（273.4% vs 2.0%，领先271.3%），Aurinia Pharmaceuticals Inc.同比增速更快（28.8% vs -1.8%），过去两年Aurinia Pharmaceuticals Inc.的营收复合增速更高（23.8% vs -4.7%）
Aurinia Pharmaceuticals是一家生物制药企业，专注于自身免疫疾病及肾脏疾病靶向疗法的研发与商业化，核心获批产品为用于治疗成人活动性狼疮性肾炎的Lupkynis，主要市场覆盖北美及欧洲地区。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
AUPH vs RMAX — 直观对比
营收规模更大
AUPH
是对方的1.1倍
$71.1M
营收增速更快
AUPH
高出30.6%
-1.8%
净利率更高
AUPH
高出271.3%
2.0%
两年增速更快
AUPH
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.1M | $71.1M |
| 净利润 | $210.8M | $1.4M |
| 毛利率 | 88.6% | — |
| 营业利润率 | 43.1% | 13.1% |
| 净利率 | 273.4% | 2.0% |
| 营收同比 | 28.8% | -1.8% |
| 净利润同比 | 14651.2% | -75.2% |
| 每股收益（稀释后） | $1.52 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AUPHRMAX
| Q4 25 | $77.1M | $71.1M | ||
| Q3 25 | $73.5M | $73.2M | ||
| Q2 25 | $70.0M | $72.8M | ||
| Q1 25 | $62.5M | $74.5M | ||
| Q4 24 | $59.9M | $72.5M | ||
| Q3 24 | $67.8M | $78.5M | ||
| Q2 24 | $57.2M | $78.5M | ||
| Q1 24 | $50.3M | $78.3M |
净利润AUPHRMAX
| Q4 25 | $210.8M | $1.4M | ||
| Q3 25 | $31.6M | $4.0M | ||
| Q2 25 | $21.5M | $4.7M | ||
| Q1 25 | $23.3M | $-2.0M | ||
| Q4 24 | $1.4M | $5.8M | ||
| Q3 24 | $14.3M | $966.0K | ||
| Q2 24 | $722.0K | $3.7M | ||
| Q1 24 | $-10.7M | $-3.4M |
毛利率AUPHRMAX
| Q4 25 | 88.6% | — | ||
| Q3 25 | 88.9% | — | ||
| Q2 25 | 89.8% | — | ||
| Q1 25 | 86.3% | — | ||
| Q4 24 | 90.7% | — | ||
| Q3 24 | 91.1% | — | ||
| Q2 24 | 84.4% | — | ||
| Q1 24 | 84.6% | — |
营业利润率AUPHRMAX
| Q4 25 | 43.1% | 13.1% | ||
| Q3 25 | 40.5% | 25.0% | ||
| Q2 25 | 28.7% | 19.3% | ||
| Q1 25 | 35.0% | 7.2% | ||
| Q4 24 | -2.8% | 5.9% | ||
| Q3 24 | 17.3% | 19.4% | ||
| Q2 24 | -2.6% | 20.6% | ||
| Q1 24 | -26.3% | 5.8% |
净利率AUPHRMAX
| Q4 25 | 273.4% | 2.0% | ||
| Q3 25 | 42.9% | 5.4% | ||
| Q2 25 | 30.7% | 6.4% | ||
| Q1 25 | 37.4% | -2.6% | ||
| Q4 24 | 2.4% | 8.0% | ||
| Q3 24 | 21.2% | 1.2% | ||
| Q2 24 | 1.3% | 4.7% | ||
| Q1 24 | -21.4% | -4.3% |
每股收益（稀释后）AUPHRMAX
| Q4 25 | $1.52 | — | ||
| Q3 25 | $0.23 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $0.01 | — | ||
| Q1 24 | $-0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.2M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $581.3M | $452.4M |
| 总资产 | $751.6M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资AUPHRMAX
| Q4 25 | $80.2M | $118.7M | ||
| Q3 25 | $72.9M | $107.5M | ||
| Q2 25 | $52.9M | $94.3M | ||
| Q1 25 | $66.1M | $89.1M | ||
| Q4 24 | $83.4M | $96.6M | ||
| Q3 24 | $36.6M | $83.8M | ||
| Q2 24 | $33.3M | $66.1M | ||
| Q1 24 | $63.9M | $82.1M |
总债务AUPHRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益AUPHRMAX
| Q4 25 | $581.3M | $452.4M | ||
| Q3 25 | $365.8M | $448.1M | ||
| Q2 25 | $335.3M | $442.4M | ||
| Q1 25 | $350.2M | $433.5M | ||
| Q4 24 | $377.5M | $429.5M | ||
| Q3 24 | $388.0M | $423.1M | ||
| Q2 24 | $364.6M | $418.4M | ||
| Q1 24 | $359.5M | $412.0M |
总资产AUPHRMAX
| Q4 25 | $751.6M | $582.5M | ||
| Q3 25 | $527.5M | $582.2M | ||
| Q2 25 | $502.6M | $574.8M | ||
| Q1 25 | $504.9M | $571.4M | ||
| Q4 24 | $550.6M | $581.6M | ||
| Q3 24 | $549.4M | $578.6M | ||
| Q2 24 | $523.5M | $571.4M | ||
| Q1 24 | $516.6M | $566.7M |
负债/权益比AUPHRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.7M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | — | $33.5M |
| 自由现金流率自由现金流/营收 | — | 47.1% |
| 资本支出强度资本支出/营收 | — | 10.4% |
| 现金转化率经营现金流/净利润 | 0.22× | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流AUPHRMAX
| Q4 25 | $45.7M | $40.9M | ||
| Q3 25 | $44.4M | $17.7M | ||
| Q2 25 | $44.2M | $4.6M | ||
| Q1 25 | $1.3M | $5.7M | ||
| Q4 24 | $30.1M | $59.7M | ||
| Q3 24 | $17.0M | $17.6M | ||
| Q2 24 | $15.8M | $15.9M | ||
| Q1 24 | $-18.6M | $9.4M |
自由现金流AUPHRMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率AUPHRMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度AUPHRMAX
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率AUPHRMAX
| Q4 25 | 0.22× | 28.39× | ||
| Q3 25 | 1.41× | 4.45× | ||
| Q2 25 | 2.06× | 0.97× | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 21.07× | 10.28× | ||
| Q3 24 | 1.19× | 18.22× | ||
| Q2 24 | 21.94× | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AUPH
| Products | $74.2M | 96% |
| License Collaboration And Royalty Revenue | $2.9M | 4% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
